Pacira proposes $250M convertible note offering due 2029; up to $50M share repurchase

Pacira BioSciences, Inc.

Proposed offering of $250M aggregate principal of Convertible Senior Notes due 2029, with initial purchasers' option for additional $37.5M.
Proceeds to repurchase portion of outstanding 0.750% 2025 Notes, fund capped call transactions, and repurchase up to $50M of common stock.
Capped call transactions expected to reduce dilution upon conversion and offset cash payments in excess of principal amount.
Entered First Amendment to Credit Agreement to permit $150M share repurchase program and the proposed note offering.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Pacira BioSciences, Inc. amended First TLA Amendment with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders (effective 2024-05-08).

Action: amendment
Agreement: credit facility
Counterparty: JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders
Effective: 2024-05-08

Exact text from the filing

On May 8, 2024, Pacira BioSciences, Inc. (the “Company”), JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders entered into a first amendment (the “First TLA Amendment”) to the Credit Agreement, dated as of March 31, 2023

View on SEC.gov

Browse all material agreements →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-058675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.